ENANTA PHARMACEUTICALS, INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
ENANTA PHARMACEUTICALS, INC (ENTA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 8.60% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 8.60%, a 72.00% increase from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 5.00%, a 127.27% increase from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 2.20%.
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.80%, a 133.33% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-09-30 | 8.60% 10-K · filed 2025-11-19 |
| 2024-09-30 | 5.00% 10-K · filed 2025-11-19 |
| 2023-09-30 | 2.20% 10-K · filed 2025-11-19 |
| 2022-09-30 | -0.80% 10-K · filed 2024-11-27 |
| 2021-09-30 | 2.40% 10-K · filed 2023-11-22 |
| 2020-09-30 | 2.80% 10-K · filed 2022-11-23 |
| 2019-09-30 | -6.70% 10-K · filed 2021-11-24 |
| 2018-09-30 | -2.80% 10-K · filed 2020-11-25 |
| 2017-09-30 | 4.50% 10-K · filed 2019-11-27 |
| 2016-09-30 | 2.60% 10-K · filed 2018-11-29 |
| 2015-09-30 | 0.50% 10-K · filed 2017-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |